Digestive and pancreatic endocrine tumors;Tumeurs endocrines digestives et pancréatiques

Hepato-Gastro

Volumn 12, Issue 5, 2005, Pages 361-365

  Cadiot, G ^a   Hammel, P ^a   Mitry, E ^a   Lombard Bohas, C ^a   Legoux, J L ^a   Michel, P ^a   Taieb J ^a   Conroy, T ^a   O'Toole, D ^a   Seitz, J F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CISPLATIN; DACARBAZINE; DIAZOXIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE; STREPTOZOCIN;

APPENDIX CANCER; CANCER CLASSIFICATION; DIGESTIVE SYSTEM TUMOR; ENDOCRINE TUMOR; FAMILIAL DISEASE; HUMAN; LIVER METASTASIS; PATHOLOGICAL ANATOMY; SHORT SURVEY;

EID: 25844498495     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Solcia E, Klöppel G, Sobin LH. World Health Organization. International histological classification of tumors. Second Edition. Springer, Berlin, 2000.
2. Elias D, Rougier P, Lasser P, Duvillard P, Venezia P, Schlumberger M, et al. Reductional major surgery and chemotherapy in multimetastatic apudomas. Ann Chir 1988; 42: 474-81.
3. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36-42.
4. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrines tumors. A 31-case French multicentric report. Ann Surg 1997; 225: 355-64.
5. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 1998; 66: 1307-12.
6. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71: 2624-30.
7. Dominguez S, Denys A, Menu Y, Ruszniewski P. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol. 1999 Oct; 31 Suppl 2: S213-5.
8. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
9. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
10. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 85: 593-6.
11. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244-8.
12. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, et al. The antitumoral effect of the long-acting somatostatine analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95: 3276-81.
13. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996; 38: 430-8.
14. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003; 21: 2689-96.
15. Oberg K, Norheim I, Lind E, Aim G, Lundqvist G, Wide L, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long term results. Cancer Treat Rep 1986; 70: 1297-304.
16. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993; 72: 3099-105.
17. Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res 1990; 50: 3413-5.
18. Andreyev HJN, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alpha-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 1995; 13: 1486-92.
19. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002; 13: 614-21.
20. Altimari A, Badrinath K, Reisel H, Prinz RA. DTIC therapy in patients with malignant intraabdominal neuroendocrine tumors. Surgery 1987; 102: 1009-17.
21. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-5.